April 2, 2026
On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and, unlike some other GLP-1s, does not need to be taken on an empty stomach.
Foundayo is the second oral GLP-1 weight loss pill approved, following the December 2025 approval of a pill form of Wegovy.
Trials showed users lost an average of 7.5% to 11.2% of their body weight, with some losing 15% or more.
Foundayo is a daily, non-injected tablet designed for convenience.
Availability & Cost: The medication is expected to ship immediately. Patients with insurance may pay as little as $25 per month with a Lilly discount card, while cash prices range from $149 to $349 per month.
Foundayo will be offered in six doses, with patients typically starting on the lowest dose and working their way up to reduce side effects. It can be taken at any time of day without meal restrictions — unlike the Wegovy pill, which must be taken on an empty stomach each morning.
The lowest dose is expected to cost about $149 a month for people paying out of pocket, in line with the Wegovy pill. Higher doses could cost as much as $349 a month. It’s unclear how many private insurers will cover the drug. Under a Trump administration plan, Medicare could begin covering the drug for some patients as soon as this summer, with copays as low as $50 a month.
Lilly also has another GLP-1 drug in development, called retatrutide, which has shown greater weight loss in trials than any other drug on the market. But the pill versions tend to lead to less weight loss than the weekly injections — a gap that could make them less appealing to patients.
People report being very successful on Zepbound and then wanting to transition to something less invasive than a weekly injection, where you have to transport it under refrigerated conditions and remember to take it once a week.
Demand for weight loss pills is strong, if Novo Nordisk’s sales are any indication. In February, Novo Nordisk said more than 170,000 people were taking the Wegovy pill after it launched in January.
Learn More About The Medical Weight Loss Market
Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast”, March 2026. This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts.
The report includes in-depth analyses of: 2024-2025 market/revenue performance, recent competitor and market developments, current dieter trends and top diet plans, and diet company advertising and marketing spending. Special emphasis and analysis of the obesity drugs market and its effect on all market segments. Coverage of cheaper compounded drugs that are not FDA-approved, new drugs entering the market.
Individual Status Reports and the effects of the obesity drugs boom on operations and revenues, for ALL major weight loss market segments… diet soft drinks, artificial sweeteners, health clubs industry, commercial weight loss chains, retail meal replacements and appetite suppressants, and low-calorie dinner entrees.
The complete report is available for sale, for $995, at: marketdataenterprises.com, or by calling Marketdata at: 813-971-8080. A Table of Contents can be found at the website.